GENFIT S.A. - American Depositary Shares (GNFT)

Competitors to GENFIT S.A. - American Depositary Shares (GNFT)

Bristol-Myers Squibb Company 

Bristol-Myers Squibb has a diverse portfolio that includes treatments for liver diseases as well as a robust pipeline that features competitive therapies for metabolic conditions, including those similar to GENFIT’s offerings. Their significant resources allow for extensive research and development, which may overshadow smaller firms like GENFIT. Additionally, BMY’s experience in the pharmaceutical industry and established relationships with healthcare providers lead to a greater market entry strength compared to GENFIT’s emerging status.

CohBar, Inc.

CohBar, Inc. is involved in the development of therapeutics targeting mitochondrial dysfunction, which has implications for a variety of diseases, including metabolic diseases that overlap with some of GENFIT's focus areas. While not a direct competitor in the exact same therapeutic space, the two companies compete for investor interest and funding in the broader area of metabolic diseases and liver-related conditions. GENFIT holds a more established position in the NASH market specifically, while CohBar is exploring a different therapeutic approach.

Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals is another player in the liver disease treatment market, particularly focusing on Hepatitis D and NASH. The competition between Eiger and GENFIT is significant as both companies attempt to carve out a niche in addressing chronic liver diseases. Whereas Eiger is concentrated on viral liver infections, GENFIT aims to provide solutions for metabolic liver disease, leading them to cater to slightly different segments within the broader liver disease market. Eiger's ongoing clinical trials give it a sense of urgency that propels innovation, while GENFIT has the benefit of a focused pipeline for a specific disease state.

Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals focuses on developing treatments for nonalcoholic steatohepatitis (NASH) and other liver-related diseases, which places it in direct competition with GENFIT, especially given that GENFIT is also targeting NASH with its pipeline of drug candidates. Both companies aim to deliver innovative therapies for chronic liver diseases, and Intercept's drug, Ocaliva, has already gained approval, giving it a first-mover advantage in the market. This regulatory head start provides Intercept with a competitive edge in terms of market presence and credibility among healthcare providers.